Vertex to Acquire Crinetics for $10 Billion in Major Rare Disease Expansion
The deal adds PALSONIFY (paltusotine) and late-stage CAH therapy to Vertex’s portfolio.
/ 2 items
The deal adds PALSONIFY (paltusotine) and late-stage CAH therapy to Vertex’s portfolio.
BioCryst Pharmaceuticals announces $700M acquisition of Astria Therapeutics, adding promising hereditary angioedema drug to expand rare disease treatment options.